Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $10.80 Average PT from Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have received an average recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $10.80.

A number of research firms have recently issued reports on XERS. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $6.90 on Friday. Xeris Biopharma has a 1 year low of $4.40 and a 1 year high of $10.08. The firm has a market cap of $1.19 billion, a PE ratio of 115.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The company has a 50 day simple moving average of $6.24 and a two-hundred day simple moving average of $6.57.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Analysts expect that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Dawn Halkuff sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director owned 95,000 shares in the company, valued at $578,550. The trade was a 17.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the sale, the insider owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,335 shares of company stock worth $766,733 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock worth $5,072,000 after purchasing an additional 156,483 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after purchasing an additional 225,602 shares during the last quarter. California State Teachers Retirement System lifted its stake in Xeris Biopharma by 19.3% in the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after purchasing an additional 29,168 shares during the last quarter. Royal Bank of Canada lifted its stake in Xeris Biopharma by 12.9% in the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after purchasing an additional 4,974 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Xeris Biopharma by 59.0% in the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after purchasing an additional 27,003 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.